Daan W. Hommes

10.6k citations

97 papers · 7.1k indexed · 4 hit papers · h-index 39

Genetics top 0.2%
Epidemiology top 0.5%
Surgery top 1%
Immunology top 1%
Molecular Biology top 10%

Co-authors: Sander J. H. van Deventer Maikel P. Peppelenbosch Guido N.J. Tytgat Hendrik M. van Dullemen Henri Braat James N. Woody Sander van Deventer Gijs R. van den Brink
Topics: Inflammatory Bowel Disease (61 papers)Microscopic Colitis (32 papers)Autoimmune and Inflammatory Disorders (7 papers)
Cited by: Genetics Internal Medicine Epidemiology
Journals: The Lancet Journal of Biological Chemistry Circulation
Partner nations: Netherlands United States Germany

In The Last Decade

Daan W. Hommes

93 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

2010 1.1k citations Gert Van Assche, Daan W. Hommes et al. profile →
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)

1995 886 citations Hendrik M. van Dullemen, Sander J. H. van Deventer et al. Gastroenterology profile →
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease

2003 555 citations Henri Braat, Daan W. Hommes et al. Gastroenterology profile →
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

1992 480 citations Daan W. Hommes et al. profile →

Peers

Countries citing papers authored by Daan W. Hommes

Since Specialization

Citations

This map shows the geographic impact of Daan W. Hommes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daan W. Hommes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daan W. Hommes more than expected).

Fields of papers citing papers by Daan W. Hommes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daan W. Hommes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daan W. Hommes. The network helps show where Daan W. Hommes may publish in the future.

Co-authorship network of co-authors of Daan W. Hommes

This figure shows the co-authorship network connecting the top 25 collaborators of Daan W. Hommes. A scholar is included among the top collaborators of Daan W. Hommes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daan W. Hommes. Daan W. Hommes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis 2012 ·Gut ·Paul Rutgeerts,Richard N. Fedorak,Daan W. Hommes,Andreas Sturm,Daniel C. Baumgart,Brian Bressler,Stefan Schreiber,John Mansfield,Marna Williams,Meina Tang,Jennifer Visich,Xiaohui Wei,Mary Keir,Diana Luca,Dimitry M. Danilenko,Jackson G. Egen,Sharon O’Byrne	111
2	A Meta-Analysis of Genome-Wide Association Scans Identifies IL18RAP, PTPN2, TAGAP, and PUS10 As Shared Risk Loci for Crohn's Disease and Celiac Disease 2011 ·PLoS Genetics ·Eleonora A. Festen,Philippe Goyette,Todd J. Green,Gabrielle Boucher,Claudine Beauchamp,Gosia Trynka,P Dubois,Caroline Lagacé,Pieter Stokkers,Daan W. Hommes,Donatella Barisani,Orazio Palmieri,Vito Annese,David A. van Heel,Rinse K. Weersma,Mark J. Daly,Cisca Wijmenga,John D. Rioux	162
3	Inflammatory bowel disease Foreword 2010 ·Expert Review of Clinical Immunology ·Stephen B. Hanauer,Daan W. Hommes	1
4	Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis 2010 ·Gut ·William J. Sandborn,(unknown),Matthew Frankel,Daan W. Hommes,James N. Lowder,L Mayer,Scott E. Plevy,Pieter Stokkers,Simon Travis,Gert Van Assche,Daniel C. Baumgart,Stephan R. Targan	58
5	5-Aminosalicylic acid inhibits TGF-β1 signalling in colorectal cancer cells 2009 ·Cancer Letters ·Pim J. Koelink,Lukas J.A.C. Hawinkels,Eliza Wiercinska,Cornelis F.M. Sier,Peter ten Dijke,C. B. H. W. Lamers,Daan W. Hommes,Hein W. Verspaget	22
6	Circulating cell death products predict clinical outcome of colorectal cancer patients 2009 ·BMC Cancer ·Pim J. Koelink,Cornelis Bhw Lamers,Daan W. Hommes,Hein W. Verspaget	46
7	Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence 2008 ·Gastrointestinal Endoscopy ·David J. van Westerloo,Erik A.J. Rauws,Daan W. Hommes,Alex F. de Vos,Tom van der Poll,Barbara Powers,Paul Fockens,Marcel G. W. Dijkgraaf,Marco J. Bruno	14
8	Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in Crohnʼs disease 2008 ·Inflammatory Bowel Diseases ·M. Meijer,Marij A.C. Mieremet-Ooms,Cornelis F.M. Sier,R. A. van Hogezand,C. B. H. W. Lamers,Daan W. Hommes,Hein W. Verspaget	20
9	MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not 2008 ·British Journal of Cancer ·Alexandra M. J. Langers,Cornelis F.M. Sier,Lukas J.A.C. Hawinkels,F J G M Kubben,W. van Duijn,J.J. van der Reijden,C. B. H. W. Lamers,Daan W. Hommes,Hein W. Verspaget	44
10	A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis 2008 ·Journal of Clinical Gastroenterology ·Daan W. Hommes,Willemien Erkelens,Cyriel Y. Ponsioen,Pieter Stokkers,(unknown),(unknown),Fiebo ten Kate,S J van Deventer	87
11	Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients 2007 ·British Journal of Cancer ·Lukas J.A.C. Hawinkels,Hein W. Verspaget,W. van Duijn,(unknown),Kim Zuidwijk,F J G M Kubben,Jan H. Verheijen,Daan W. Hommes,C. B. H. W. Lamers,Cornelis F.M. Sier	72
12	Abstract 1497: Enhanced atherogenesis and altered High Density Lipoprotein in patients with Crohn's Disease 2006 ·Circulation ·Sander I. van Leuven,(unknown),(unknown),S J van Deventer,John J.P. Kastelein,Erik S.G. Stroes,Eric de Groot,Daan W. Hommes	1
13	A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn's disease 2006 ·Gastroenterology ·G. D’Haens,Daan W. Hommes,(unknown),Martine De Vos,(unknown),Gert Van Assche,Guy Lambrecht,J.-C. Coche,Séverine Vermeire,(unknown)	20
14	Immunology of Crohn's Disease 2006 ·Annals of the New York Academy of Sciences ·Henri Braat,Maikel P. Peppelenbosch,Daan W. Hommes	27
15	Short-Term Outcomes after Laparoscopic Ileocolic Resection for Crohn’s Disease 2006 ·Digestive Surgery ·Sebastiaan W. Polle,Jan Wind,Dirk T. Ubbink,Daan W. Hommes,Dirk J. Gouma,Willem A. Bemelman	51
16	Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study 2006 ·Alimentary Pharmacology & Therapeutics ·Geert D’Haens,Daan W. Hommes,L.G.J.B. Engels,(unknown),(unknown),Patrick Connor,John Ramage,Olivier Dewit,Mary Palmen,David D. Stephenson,Richard J. Joseph	66
17	Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function 2004 ·American Journal of Clinical Nutrition ·Henri Braat,Jan Van den Brande,(unknown),Daan W. Hommes,Maikel P. Peppelenbosch,Sander van Deventer	180
18	Increased expression of DC‐SIGN⁺IL‐12⁺IL‐18⁺ and CD83⁺IL‐12^–IL‐18^– dendritic cell populations in the colonic mucosa of patients with Crohn's disease 2002 ·European Journal of Immunology ·Anje A. te Velde,Yvette van Kooyk,Henri Braat,Daan W. Hommes,Trees A. M. Dellemijn,J. Frederik M. Slors,Sander J. H. van Deventer,Florry A. Vyth‐Dreese	117
19	Beneficial Effect of Treatment with a Monoclonal Anti-Tumor Necrosis Factor-α Antibody on Markers of Coagulation and Fibrinolysis in Patients with Active Crohn’s Disease 1997 ·Pathophysiology of Haemostasis and Thrombosis ·Daan W. Hommes,Hendrik M. van Dullemen,Micha Levi,Arie van der Ende,J. Woody,G. N. J. Tytgat,Sander J. H. van Deventer	38
20	Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis 1996 ·European Journal of Gastroenterology & Hepatology ·John Meenan,(unknown),Daan W. Hommes,(unknown),Fibo J. ten Kate,Michael L. Wood,Michael R. Whittaker,Guido N.J. Tytgat,S J van Deventer	24

About Daan W. Hommes

Daan W. Hommes is a scholar working on Genetics, Gastroenterology and Epidemiology, having authored 97 papers that have together received 7.1k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (61 papers), Microscopic Colitis (32 papers) and Autoimmune and Inflammatory Disorders (7 papers). The work is most often cited by research in Genetics (3.8k citations), Internal Medicine (435 citations) and Epidemiology (2.5k citations). Daan W. Hommes has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Sander J. H. van Deventer, Maikel P. Peppelenbosch, Guido N.J. Tytgat, Hendrik M. van Dullemen, Henri Braat, James N. Woody, Sander van Deventer, Gijs R. van den Brink, Gert Van Assche and Axel Dignaß. Their work appears in journals such as The Lancet, Journal of Biological Chemistry and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact